Diagnostics.ai
Private Company
Total funding raised: $2.5M
Overview
Diagnostics.ai has established itself as a key enabler of laboratory efficiency and accuracy with its clinically validated, AI-driven platform for PCR data analysis. Its core product, pcr.ai, automates the review of real-time PCR curves, performs automated QC checks, and facilitates seamless data management and LIMS integration, which is trusted by major laboratories like Quest Diagnostics and several UK NHS trusts. The company is positioned in the high-growth digital diagnostics and lab automation sector, leveraging regulatory certifications (CE-IVDR, ISO27001) and a focus on data security to drive adoption. Its business model centers on providing software-as-a-service to diagnostic labs, moving them towards fully automated resulting.
Technology Platform
AI-powered software platform (pcr.ai) for automated analysis, quality control, and reporting of real-time PCR data. Features a CE-IVDR certified analysis engine, automated QC rules (Westgard), LIMS integration, and multi-device management.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Competes with embedded software from qPCR instrument manufacturers (Thermo Fisher, Bio-Rad, Roche) and other independent lab informatics/AI software providers. Differentiation is achieved through dedicated CE-IVDR certification for the AI engine, a focus on end-to-end workflow integration, and proven adoption by major reference laboratories.